Compare Amylx Pharmaceuticals Inc (AMLX) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance

Amylx Pharmaceuticals IncTrade

Schwab US Dividend Equity ETFTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Schwab US Dividend Equity ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Schwab US Dividend Equity ETF trades at $34.31. Which is the better fit depends on your goals.

	AMLX	SCHD
Market Cap	$2.53B	—
Sector	Health	Broad Market / Factor
52-Week High	$24.19	$34.27
52-Week Low	$7.82	$26.44
Enterprise Value	$2.28B	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Schwab US Dividend Equity ETF

SCHD, the Schwab U.S. Dividend Equity ETF, trades at $33.90, up 0.59% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on high-quality U.S. dividend-paying stocks, offering income stability. Recent news highlights its popularity among retirees for generating passive income, with institutional buying activity noted in Q2 2026 filings.

The outlook for SCHD remains positive for income-focused investors, leveraging dividend growth and low costs. Risks include interest rate sensitivity and market volatility affecting dividend stocks. Analyst sentiment is generally favorable, emphasizing its role in diversified retirement portfolios.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMLX

Amylyx shifts focus to endocrine drug avexitide with strong cash runway into 2028 and key trial results in 2026Seeking Alpha · 4 days agoBullish View details →

SCHD

SCHD ETF's index reshuffle caused unexpected high taxable distributions in 2024, hitting taxable accounts hard.24/7 Wall Street · 13 hours agoNeutral Vanguard High Dividend Yield ETF lags S&P 500 by $141K over 10 years despite dividends.24/7 Wall Street · 1 day agoBearish WisdomTree U.S. Total Dividend ETF (DTD) rated 'hold' for balanced factors but overlaps 57% with S&P 500 ETFs.Seeking Alpha · 1 day agoNeutral View details →

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

About Schwab US Dividend Equity ETF

SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.